Is the price fair?
What TAK's price assumes
Takeda Pharmaceutical Company Limited did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.00× revenue.
0.00
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 0.00
Price / book · as of 2025-FY
- EV / sales
- 0.25
EV / sales
Details›
- Price / book2025-FY
- 0.00
- EV / EBIT2025-FY
- 2.75
- EV / sales2025-FY
- 0.25
- Market capitalisation
- $49.4B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #14 of 28 by Smart Score